Nat. Med. 24, 282–291 (2018); published online 12 February 2018; corrected after print 6 March 2018
In the version of this article initially published, Omid Shah's name was misspelled as Omid Sha. The error has been corrected in the PDF and HTML versions of this article.
Additional information
The online version of the original article can be found at https://doi.org/10.1038/nm.4484
Rights and permissions
About this article
Cite this article
Mathew, N., Baumgartner, F., Braun, L. et al. Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med 24, 526 (2018). https://doi.org/10.1038/nm0418-526c
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/nm0418-526c
This article is cited by
-
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
International Journal of Hematology (2022)
